Stryker Corporation (SYK) Shares Sold by DE Burlo Group Inc.

DE Burlo Group Inc. lessened its stake in Stryker Corporation (NYSE:SYK) by 13.8% in the fourth quarter, HoldingsChannel reports. The firm owned 72,050 shares of the medical technology company’s stock after selling 11,550 shares during the quarter. Stryker accounts for 2.3% of DE Burlo Group Inc.’s portfolio, making the stock its 16th largest position. DE Burlo Group Inc.’s holdings in Stryker were worth $11,156,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Coldstream Capital Management Inc. grew its stake in Stryker by 3.7% in the 2nd quarter. Coldstream Capital Management Inc. now owns 17,445 shares of the medical technology company’s stock valued at $2,421,000 after acquiring an additional 626 shares during the last quarter. Retirement Systems of Alabama grew its stake in Stryker by 2.5% in the 3rd quarter. Retirement Systems of Alabama now owns 234,870 shares of the medical technology company’s stock valued at $33,356,000 after acquiring an additional 5,656 shares during the last quarter. Toronto Dominion Bank grew its stake in Stryker by 25.8% in the 2nd quarter. Toronto Dominion Bank now owns 105,403 shares of the medical technology company’s stock valued at $14,625,000 after acquiring an additional 21,585 shares during the last quarter. Colonial Trust Advisors grew its stake in Stryker by 56.1% in the 2nd quarter. Colonial Trust Advisors now owns 23,446 shares of the medical technology company’s stock valued at $3,254,000 after acquiring an additional 8,426 shares during the last quarter. Finally, Cornerstone Capital Management Holdings LLC. grew its stake in Stryker by 3.1% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 55,255 shares of the medical technology company’s stock valued at $7,847,000 after acquiring an additional 1,683 shares during the last quarter. Institutional investors and hedge funds own 74.71% of the company’s stock.

In related news, insider Graham A. Mclean sold 2,984 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $160.53, for a total value of $479,021.52. Following the transaction, the insider now owns 9,100 shares in the company, valued at $1,460,823. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Howard E. Cox, Jr. sold 7,400 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $164.09, for a total transaction of $1,214,266.00. The disclosure for this sale can be found here. Insiders sold 16,840 shares of company stock worth $2,749,989 over the last three months. Corporate insiders own 7.40% of the company’s stock.

Shares of Stryker Corporation (NYSE SYK) opened at $156.24 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. Stryker Corporation has a 12-month low of $124.61 and a 12-month high of $170.00. The stock has a market cap of $57,904.67, a P/E ratio of 23.82, a P/E/G ratio of 2.22 and a beta of 0.70.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business had revenue of $3.47 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same period last year, the company earned $1.78 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. analysts anticipate that Stryker Corporation will post 7.12 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Investors of record on Thursday, March 29th will be given a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.20%. Stryker’s dividend payout ratio is presently 70.15%.

A number of equities research analysts recently commented on the stock. SunTrust Banks reissued a “buy” rating and issued a $179.00 price objective (up from $161.00) on shares of Stryker in a research note on Friday, January 26th. Cantor Fitzgerald reissued a “hold” rating and issued a $163.00 price objective on shares of Stryker in a research note on Tuesday, January 30th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research note on Wednesday, January 31st. Leerink Swann increased their price objective on shares of Stryker from $177.00 to $184.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, Oppenheimer reissued a “hold” rating and issued a $165.00 price objective on shares of Stryker in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $162.50.

TRADEMARK VIOLATION NOTICE: “Stryker Corporation (SYK) Shares Sold by DE Burlo Group Inc.” was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/02/15/stryker-corporation-syk-shares-sold-by-de-burlo-group-inc.html.

About Stryker

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply